# C_2011153EN.01001701.xml

| 24.5.2011 | EN | Official Journal of the European Union | C 153/17 |
| --- | --- | --- | --- |

24.5.2011

EN

Official Journal of the European Union

C 153/17

---

Prior notification of a concentration

(Case COMP/M.6205 — Eli Lilly/Janssen Pharmaceutica Animal Health Business Assets)

(Text with EEA relevance)

2011/C 153/09

| 1. | On 13 May 2011, the Commission received a notification of a proposed concentration pursuant to Article 4 and following a referral pursuant to Article 4(5) of Council Regulation (EC) No 139/2004 (1) by which the undertaking Eli Lilly and Company (‘Eli Lilly’, the US) acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of Janssen Animal Health Business Assets (JAH) of Janssen Pharmaceutica NV (‘Janssen’, Belgium) by way of purchase of assets. |
| --- | --- |

1.

On 13 May 2011, the Commission received a notification of a proposed concentration pursuant to Article 4 and following a referral pursuant to Article 4(5) of Council Regulation (EC) No 139/2004 (1) by which the undertaking Eli Lilly and Company (‘Eli Lilly’, the US) acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of Janssen Animal Health Business Assets (JAH) of Janssen Pharmaceutica NV (‘Janssen’, Belgium) by way of purchase of assets.

1

| 2. | The business activities of the undertakings concerned are:






  — | Eli Lilly: discovery, development, manufacture and sale of pharmaceutical products for humans and animals, |
| --- | --- | --- |

2.

The business activities of the undertakings concerned are:

—

Eli Lilly: discovery, development, manufacture and sale of pharmaceutical products for humans and animals,

| — | JAH: development and sale of animal health pharmaceuticals for companion animals and livestock (mainly swine and poultry). |
| --- | --- |

—

JAH: development and sale of animal health pharmaceuticals for companion animals and livestock (mainly swine and poultry).

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope the EC Merger Regulation. However, the final decision on this point is reserved. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope the EC Merger Regulation. However, the final decision on this point is reserved.

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by e-mail to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number COMP/M.6205 — Eli Lilly/Janssen Pharmaceutica Animal Health Business Assets, to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| J-70 |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by e-mail to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number COMP/M.6205 — Eli Lilly/Janssen Pharmaceutica Animal Health Business Assets, to the following address:

European Commission

Directorate-General for Competition

Merger Registry

J-70

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘EC Merger Regulation’).

1

---